ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products

REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.

Read more at prnewswire.com